Search
Mosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate.
Benidipine
go.drugbank.com/drugs/DB09231Investigational[A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]
Vusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational[L64061] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009.
Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February
Benzoylecgonine
go.drugbank.com/drugs/DB01515ExperimentalIllicitIt is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for the relief of muscle pain that is not FDA approved or on the market in the United States.
Potassium hydroxide
go.drugbank.com/drugs/DB11153Approved[L1946,L1951] This ingredient has been considered as generally safe as a direct human food ingredient by the FDA, based upon the observance of several good manufacturing practice conditions of use.
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma